Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS Cash-to-Debt is 71.27 as of Jun. 2026, which is 88% below its 10-year median of 580.35. The stock has 4 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 92.75% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Genetic Signatures's cash to debt ratio for the quarter that ended in Jun. 2026 was 71.27.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Genetic Signaturescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Genetic Signatures's Cash-to-Debt or its related term are showing as below:
ASX:GSS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 29.69 Med: 580.35 Max: No Debt
Current: 71.27
During the past 12 years, Genetic Signatures's highest Cash to Debt Ratio was No Debt. The lowest was 29.69. And the median was 580.35.
ASX:GSS's Cash-to-Debt is ranked better than 92.75% of 207
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.03
vs ASX:GSS: 71.27
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Genetic Signatures Cash-to-Debt Related Terms
Genetic Signatures Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:GSS vs TMO, DHR, NTRA: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a Cash-to-Debt of 71.27 as of Jun. 2026. This is 88% below median its historical median of 580.35. Over the past decade, Genetic Signatures' Cash-to-Debt has ranged from 29.69 to 10,000.00. According to the industry distribution chart, Genetic Signatures ranks #15 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 7.2%.
Is Genetic Signatures' Cash-to-Debt too high?
Genetic Signatures' current Cash-to-Debt of 71.27 is 88% below median its 10-year median of 580.35. Over the past 10 years, this metric has ranged from a low of 29.69 to a high of 10,000.00. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.03. Genetic Signatures' value of 71.27 is 6819.4% above this industry median. Based on the distribution chart, Genetic Signatures ranks #15 out of 207 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Genetic Signatures' Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #15 out of 207 companies for Cash-to-Debt. This places Genetic Signatures in the top 7% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.03. Genetic Signatures' value of 71.27 is 6819.4% above this benchmark. Historically, Genetic Signatures' own Cash-to-Debt has ranged from 29.69 to 10,000.00 over the past decade. While the company's 10-year median is 580.35 vs. the industry median of 1.03, Genetic Signatures has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.03, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current Cash-to-Debt of 71.27 is 6819.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Cash-to-Debt is 71.27, which is 88% below median its own 10-year median of 580.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.34, compared to a current price of A$0.09 — trading 74.4% below its estimated fair value. The current Cash-to-Debt is 71.27, which is 88% below median its 10-year median of 580.35 and 6819.4% above the Medical Diagnostics & Research industry median of 1.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Cash-to-Debt is 71.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
